Mustang Bio to Participate in Chardan’s 5th Annual Genetic Medicines Manufacturing Summit
21. April 2021 08:00 ET
|
Mustang Bio, Inc.
WORCESTER, Mass., April 21, 2021 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in...
Mustang Bio Reports Full-Year 2020 Financial Results and Recent Corporate Highlights
24. März 2021 16:30 ET
|
Mustang Bio, Inc.
NEW YORK, March 24, 2021 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and...
Mustang Bio to Participate in Three March 2021 Virtual Investor Conferences
04. März 2021 08:00 ET
|
Mustang Bio, Inc.
WORCESTER, Mass., March 04, 2021 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in...
Mustang Bio Joins Global Movement to Raise Awareness for Rare Diseases and Supports Rare Disease Day®
26. Februar 2021 08:00 ET
|
Mustang Bio, Inc.
WORCESTER, Mass., Feb. 26, 2021 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in...
Mustang Bio Provides Updates on its Lentiviral Gene Therapies for the Treatment of X-linked Severe Combined Immunodeficiency (“XSCID”)
02. Februar 2021 07:30 ET
|
Mustang Bio, Inc.
FDA removes clinical hold for pivotal Phase 2 MB-107 clinical trial Company plans to enroll first patient in MB-107 pivotal trial in the second quarter of 2021 Clinical outcomes in investigator-IND...
Mustang Bio to Participate in Three January 2021 Virtual Investor Conferences
05. Januar 2021 08:30 ET
|
Mustang Bio, Inc.
WORCESTER, Mass., Jan. 05, 2021 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in...
Mustang Bio and City of Hope Announce Initiation of Phase 1 Clinical Trial of MB-101 (IL13Rα2-specific CAR T cells) to Treat Leptomeningeal Brain Tumors
21. Dezember 2020 08:00 ET
|
Mustang Bio, Inc.
WORCESTER, Mass., Dec. 21, 2020 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in...
Mustang Bio Announces Interim Phase 1/2 Data for MB-106 in Patients with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
07. Dezember 2020 07:30 ET
|
Mustang Bio, Inc.
Data presented at the 62nd American Society of Hematology (ASH) Annual Meetingshow extremely favorable safety profile and clinical activity 89% overall response rate and 44% complete response rate in...
Mustang Bio to Host Key Opinion Leader Call on MB-106 for the Treatment of Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma
01. Dezember 2020 08:00 ET
|
Mustang Bio, Inc.
WORCESTER, Mass., Dec. 01, 2020 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in...
Mustang Bio Announces Positive Opinion from the European Medicines Agency on Orphan Drug Designation for Its Lentiviral Gene Therapy for the Treatment of X-linked Severe Combined Immunodeficiency (“XSCID”)
24. November 2020 08:00 ET
|
Mustang Bio, Inc.
WORCESTER, Mass., Nov. 24, 2020 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in...